Skip to content Skip to footer
Subscribe Now
WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (February 10th, 2025 – February 14th, 2025)

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Animal Health & Biosimilars. Check out our full report below:      Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn's Disease  Read More: Eli Lilly  Regeneron Reveals Data from Extended P-III (PULSAR) Trial of Eylea HD for Wet Age-related Macular Degeneration  Read…
February 14, 2025

Read more

Reuters Events Digital Health 2025
EVENTS

Reuters Events: Digital Health 2025

Join us for Reuters Events Digital Health 2025 on 12-13 May in Nashville, where we tackle the critical issues plaguing the healthcare sector today. As organizations face a stretched workforce and an outdated digital infrastructure, the urgency for transformation has never been greater. Current models of care are unsustainable, especially when addressing the diverse needs of an…
February 14, 2025

Read more

PharmaShots Magazine-February 2025 Edition
MAGAZINE

PharmaShots Magazine-February 2025 Edition

After successfully navigating the healthcare landscapes of the US, EU, and China, PharmaShots Magazine brings a comprehensive take on the Japanese Healthcare System. Japan ranked second in healthcare innovation owing to diverse positive parameters like advanced medical infrastructure, learned professionals, and more. In 2023, Japan allocated 11.4 percent of its GDP to enhancing healthcare capabilities.  …
February 13, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (February 3, 2025 – February 7, 2025)

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Animal Health & DigiHealth. Check out our full report below:      Algiax Pharmaceuticals Reports Topline Data from P-IIa Trial of AP-325 for Neuropathic Pain  Read More: Algiax Pharmaceuticals  Pfizer Reveals Data from the P-III (BREAKWATER) trial of Braftovi Regimen in Patients with Metastatic…
February 7, 2025

Read more

Biopharma M&A Top 20 2024
TOP 20

Top 20 Biopharma M&A of 2024 by Total Deal Value

Top 20 Biopharma M&A of 2024 by Total Deal Value Shots: Dealmaking in 2024 experienced fluctuations due to regulatory challenges and increasing pressure from the Inflation Reduction Act The highest-value deal of the year was Vertex’s acquisition of Alpine Immune Sciences for $4.9B, followed by Gilead’s acquisition of CymaBay for $4.3B and Lilly’s acquisition of…
February 6, 2025

Read more

Key Biosimilars Events of January 2025
INSIGHTS+

Key Biosimilars Events of January 2025

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        A major highlight was the Samsung Bioepis & Teva Partners to Commercialize Epysqli in…
February 4, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (January 27, 2025 – January 31, 2025)

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & DigiHealth. Check out our full report below:      Merck and Eisai Reveal Latest Data from P-III (LEAP-015) Trial of Keytruda (pembrolizumab) and Lenvima (lenvatinib) Regimen to Treat Gastroesophageal Adenocarcinoma  Read More: Merck and Eisai  Novo Nordisk Completes P-Ib/IIa Study…
January 31, 2025

Read more

New Drug Designations - December 2024
INSIGHTS+

New Drug Designations – December 2024

Shots:   PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, MHLW and NMPA   The December 2024 report covers designations granted to 43 drugs and 3 devices, encompassing 13 small molecules, 10 biologics, 7 cell and gene therapies & 3 medical devices among others  Significant…
January 31, 2025

Read more

Viewpoints_Mina Makar
VIEWPOINTS

Cardiology Care and Beyond: Mina Makar from AstraZeneca in a Riveting Dialogue Exchange with PharmaShots

Shots: At ESC 2024, AstraZeneca presented insights from the real-world OverTTuRe study, exploring the challenges of early diagnosis in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) Mina Makar, SVP and Commercial Lead of the Global Cardiovascular, Renal, and Metabolism (CVRM) Biopharmaceuticals Business Unit at AstraZeneca, shared real-world insights on how ATTR-CM manifests as cardiac symptoms Mina highlighted the…
January 27, 2025

Read more

Load more